Co-Diagnostics Reports Full Year 2025 Financial Results

Core Insights - Co-Diagnostics reported a significant decline in revenue for the full year 2025, with total revenue of $0.6 million compared to $3.9 million in 2024, primarily due to lower grant revenue [2] - The company experienced an operating loss of $50.2 million in 2025, up from a loss of $40.1 million in 2024, largely driven by an $18.9 million non-cash impairment charge related to intangible assets [2][3] - The net loss for 2025 was $46.9 million, or $35.25 per share, compared to a net loss of $37.6 million, or $37.22 per share in 2024, reflecting the impact of impairment charges and reduced grant revenue [2][3] Financial Performance - Revenue for 2025 was $0.6 million, a decrease of 84% from $3.9 million in 2024 [2] - Operating expenses rose to $50.6 million in 2025 from $43.0 million in 2024, influenced by the impairment charge [2] - Adjusted EBITDA loss improved to $28.0 million in 2025 from a loss of $33.5 million in 2024 [2] Cash Position - As of December 31, 2025, cash, cash equivalents, and marketable investment securities totaled $11.9 million, down from $29.7 million at the end of 2024 [2] - The company closed two offerings, raising $3.8 million and $7.0 million through the sale of common stock [2] Strategic Developments - Co-Diagnostics is advancing its joint ventures, including CoSara Diagnostics in India and CoMira Diagnostics in Saudi Arabia, focusing on regulatory progress and manufacturing readiness [2][3] - The company is progressing with clinical evaluations for an upper respiratory multiplex test and expanding its AI capabilities within its diagnostic platform [2][3] - A new international patent was granted in Australia, enhancing the company's intellectual property portfolio [2] Future Outlook - The CEO emphasized the company's focus on executing its strategy centered on expanding its global footprint and advancing clinical programs toward regulatory milestones [3] - Plans for an initial FDA 510(k) submission for an upper respiratory test are underway, with the potential to incorporate COVID testing later if necessary [3]